Gil Ho Young, Park Sungchul, Kim Na Eun, Choi Yi Hwa, Kim Jae Hyung, Choi Sooil, Kim Hyun Joong, Koh Jae Chul, Lee Byung Ho, Lee Sook Young, Min Sang Kee, Kim Bora, Lee Hye Seon, Jeong Hae Won, Park Ji Hyun, Park Bumhee, Choi Jong Bum
Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Department of Anesthesiology and Pain Medicine, Cha Bundang Medical Center, Cha University School of Medicine, Seongnam 13496, Korea.
J Clin Med. 2019 Jul 10;8(7):1009. doi: 10.3390/jcm8071009.
Osteoarthritis (OA) is considered to be one of the most disabling diseases. The intra-articular opioid injection has been widely studied for its simplicity, safety, and efficacy in OA. In this study, however, we suggest a novel method of buprenorphine transdermal patch (BTDP) to painful knee joints of OA patients, instead of intra-articular opioid injection, and subsequently compared the knee application with conventional chest application. We retrospectively enrolled 213 patients with knee OA who did not respond to conventional therapy. The Numeric Rating Scale (NRS), adverse effects, and compliance were recorded before and after the application of the BTDP. All parameters were compared between the knee applied group and the chest applied group. After the BTDP application, the NRS score in the knee applied group was lower than that of the chest applied group ( = 0.007). NRS scores after buprenorphine patch decreased to 2.21 ± 0.77, and 2.55 ± 0.71 in the chest applied group and the knee applied group, respectively. The adverse effects were 19.32% in the knee applied group, and 64.00% in the chest applied group. The compliances were 82.95% and 37.60% in the knee applied group and chest applied group, respectively. This novel application of BTDP directly to the painful knee joint of knee OA patients led to a decrease in the NRS score, adverse effects, and an increase in compliance compared with the chest application method.
骨关节炎（OA）被认为是最致残的疾病之一。关节内注射阿片类药物因其在OA治疗中的简便性、安全性和有效性而得到广泛研究。然而，在本研究中，我们提出了一种将丁丙诺啡透皮贴剂（BTDP）应用于OA患者疼痛膝关节的新方法，以替代关节内注射阿片类药物，随后将膝关节应用与传统的胸部应用进行了比较。我们回顾性纳入了213例对传统治疗无反应的膝关节OA患者。在应用BTDP之前和之后记录数字评分量表（NRS）、不良反应和依从性。对膝关节应用组和胸部应用组的所有参数进行比较。应用BTDP后，膝关节应用组的NRS评分低于胸部应用组（=0.007）。丁丙诺啡贴剂应用后，胸部应用组和膝关节应用组的NRS评分分别降至2.21±0.77和2.55±0.71。膝关节应用组的不良反应发生率为19.32%，胸部应用组为64.00%。膝关节应用组和胸部应用组的依从性分别为82.95%和37.60%。与胸部应用方法相比，将BTDP直接应用于膝关节OA患者疼痛的膝关节的这种新应用导致NRS评分降低、不良反应减少和依从性增加。
